Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71(1):7–33. https://doi.org/10.3322/caac.21654

PubMed  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660

PubMed  Google Scholar 

Niu FY, Zhou Q, Yang JJ, Zhong WZ, Chen ZH, Deng W, He YY, Chen HJ, Zeng Z, Ke EE, Zhao N, Zhang N, Sun HW, Zhang QY, Xie Z, Zhang XC, Wu YL (2016) Distribution and prognosis of uncommon metastases from non-small cell lung cancer. BMC Cancer 16:149. https://doi.org/10.1186/s12885-016-2169-5

CAS  PubMed  PubMed Central  Google Scholar 

Boire A, Brastianos PK, Garzia L, Valiente M (2020) Brain metastasis. Nat Rev Cancer 20(1):4–11. https://doi.org/10.1038/s41568-019-0220-y

CAS  PubMed  Google Scholar 

Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378(2):113–125. https://doi.org/10.1056/NEJMoa1713137

CAS  PubMed  Google Scholar 

Dong RF, Zhu ML, Liu MM, Xu YT, Yuan LL, Bian J, Xia YZ, Kong LY (2021) EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research. Pharmacol Res 167:105583. https://doi.org/10.1016/j.phrs.2021.105583

CAS  PubMed  Google Scholar 

Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497–1500. https://doi.org/10.1126/science.1099314

CAS  PubMed  Google Scholar 

Liu S, Wu F, Li X, Zhao C, Jia Y, Jia K, Han R, Qiao M, Li W, Yu J, Zhou F, Xiong A, Chen B, Fan J, Ren S, Zhou C (2021) patients with short PFS to EGFR-TKIs predicted better response to subsequent anti-PD-1/PD-L1 based immunotherapy in EGFR common mutation NSCLC. Front Oncol 11:639947. https://doi.org/10.3389/fonc.2021.639947

PubMed  PubMed Central  Google Scholar 

Wu SG, Shih JY (2018) Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer 17(1):38. https://doi.org/10.1186/s12943-018-0777-1

CAS  PubMed  PubMed Central  Google Scholar 

Rebuzzi SE, Alfieri R, La Monica S, Minari R, Petronini PG, Tiseo M (2020) Combination of EGFR-TKIs and chemotherapy in advanced EGFR mutated NSCLC: review of the literature and future perspectives. Crit Rev Oncol Hematol 146:102820. https://doi.org/10.1016/j.critrevonc.2019.102820

PubMed  Google Scholar 

Chetan MR, Gleeson FV (2021) Radiomics in predicting treatment response in non-small-cell lung cancer: current status, challenges and future perspectives. Eur Radiol 31(2):1049–1058. https://doi.org/10.1007/s00330-020-07141-9

PubMed  Google Scholar 

Thompson JC, Yee SS, Troxel AB, Savitch SL, Fan R, Balli D, Lieberman DB, Morrissette JD, Evans TL, Bauml J, Aggarwal C, Kosteva JA, Alley E, Ciunci C, Cohen RB, Bagley S, Stonehouse-Lee S, Sherry VE, Gilbert E, Langer C, Vachani A, Carpenter EL (2016) Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA. Clin Cancer Res 22(23):5772–5782. https://doi.org/10.1158/1078-0432.Ccr-16-1231

CAS  PubMed  PubMed Central  Google Scholar 

Barnet MB, O’Toole S, Horvath LG, Selinger C, Yu B, Ng CC, Boyer M, Cooper WA, Kao S (2017) EGFR-co-mutated advanced NSCLC and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol 12(3):585–590. https://doi.org/10.1016/j.jtho.2016.09.001

PubMed  Google Scholar 

Lambin P, Leijenaar RTH, Deist TM, Peerlings J, de Jong EEC, van Timmeren J, Sanduleanu S, Larue R, Even AJG, Jochems A, van Wijk Y, Woodruff H, van Soest J, Lustberg T, Roelofs E, van Elmpt W, Dekker A, Mottaghy FM, Wildberger JE, Walsh S (2017) Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 14(12):749–762. https://doi.org/10.1038/nrclinonc.2017.141

PubMed  Google Scholar 

Bera K, Braman N, Gupta A, Velcheti V, Madabhushi A (2022) Predicting cancer outcomes with radiomics and artificial intelligence in radiology. Nat Rev Clin Oncol 19(2):132–146. https://doi.org/10.1038/s41571-021-00560-7

CAS  PubMed  Google Scholar 

Chen BT, Jin T, Ye N, Mambetsariev I, Daniel E, Wang T, Wong CW, Rockne RC, Colen R, Holodny AI, Sampath S, Salgia R (2020) Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases. Magn Reson Imaging 69:49–56. https://doi.org/10.1016/j.mri.2020.03.002

CAS  PubMed  PubMed Central  Google Scholar 

Ahn SJ, Kwon H, Yang JJ, Park M, Cha YJ, Suh SH, Lee JM (2020) Contrast-enhanced T1-weighted image radiomics of brain metastases may predict EGFR mutation status in primary lung cancer. Sci Rep 10(1):8905. https://doi.org/10.1038/s41598-020-65470-7

CAS  PubMed  PubMed Central  Google Scholar 

Wang G, Wang B, Wang Z, Li W, Xiu J, Liu Z, Han M (2021) Radiomics signature of brain metastasis: prediction of EGFR mutation status. Eur Radiol 31(7):4538–4547. https://doi.org/10.1007/s00330-020-07614-x

CAS  PubMed  Google Scholar 

Langley RR, Fidler IJ (2013) The biology of brain metastasis. Clin Chem 59(1):180–189. https://doi.org/10.1373/clinchem.2012.193342

CAS  PubMed  Google Scholar 

Doron H, Pukrop T, Erez N (2019) A blazing landscape: neuroinflammation shapes brain metastasis. Cancer Res 79(3):423–436. https://doi.org/10.1158/0008-5472.Can-18-1805

CAS  PubMed  PubMed Central  Google Scholar 

Berghoff AS, Rajky O, Winkler F, Bartsch R, Furtner J, Hainfellner JA, Goodman SL, Weller M, Schittenhelm J, Preusser M (2013) Invasion patterns in brain metastases of solid cancers. Neuro Oncol 15(12):1664–1672. https://doi.org/10.1093/neuonc/not112

PubMed  PubMed Central  Google Scholar 

Zakaria R, Platt-Higgins A, Rathi N, Radon M, Das S, Das K, Bhojak M, Brodbelt A, Chavredakis E, Jenkinson MD, Rudland PS (2018) T-cell densities in brain metastases are associated with patient survival times and diffusion tensor MRI changes. Cancer Res 78(3):610–616. https://doi.org/10.1158/0008-5472.Can-17-1720

CAS  PubMed  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026

CAS  PubMed  Google Scholar 

Kanungo M, Kanungo T, Mount DM, Netanyahu NS, Piatko CD, Silverman R, Wu AY (2002) An efficient k-means clustering algorithm: analysis and implementation. IEEE Trans Pattern Anal Mach Intell 24(7):881–892. https://doi.org/10.1109/TPAMI.2002.1017616

Google Scholar 

Johnson SC (1967) Hierarchical clustering schemes. Psychometrika 32(3):241–254. https://doi.org/10.1007/bf02289588

CAS  PubMed  Google Scholar 

van Griethuysen JJM, Fedorov A, Parmar C, Hosny A, Aucoin N, Narayan V, Beets-Tan RGH, Fillion-Robin JC, Pieper S, Aerts H (2017) Computational radiomics system to decode the radiographic phenotype. Cancer Res 77(21):e104–e107. https://doi.org/10.1158/0008-5472.Can-17-0339

PubMed  PubMed Central  Google Scholar 

Bartko JJ (1966) The intraclass correlation coefficient as a measure of reliability. Psychol Rep 19(1):3–11. https://doi.org/10.2466/pr0.1966.19.1.3

CAS  PubMed  Google Scholar 

Sakamoto Y, Ishiguro M, Kitagawa GJD (1986) Akaike information criterion statistics, vol 81. D. Reidel, The Netherlands, p 26853

Google Scholar 

DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44(3):837–845. https://doi.org/10.2307/2531595

CAS  PubMed  Google Scholar 

Park YW, An C, Lee J, Han K, Choi D, Ahn SS, Kim H, Ahn SJ, Chang JH, Kim SH, Lee SK (2021) Diffusion tensor and postcontrast T1-weighted imaging radiomics to differentiate the epidermal growth factor receptor mutation status of brain metastases from non-small cell lung cancer. Neuroradiology 63(3):343–352. https://doi.org/10.1007/s00234-020-02529-2

PubMed  Google Scholar 

Yang C, Chen W, Gong G, Li Z, Qiu Q, Yin Y (2020) Application of CT radiomics features to predict the EGFR mutation status and therapeutic sensitivity to TKIs of advanced lung adenocarcinoma. Transl Cancer Res 9(11):6683–6690. https://doi.org/10.21037/tcr-20-1216

CAS  PubMed  PubMed Central  Google Scholar 

Abdurixiti M, Nijiati M, Shen R, Ya Q, Abuduxiku N, Nijiati M (2021) Current progress and quality of radiomic studies for predicting EGFR mutation in patients with non-small cell lung cancer using PET/CT images: a systematic review. Br J Radiol 94(1122):20201272. https://doi.org/10.1259/bjr.20201272

PubMed  PubMed Central  Google Scholar 

Song J, Shi J, Dong D, Fang M, Zhong W, Wang K, Wu N, Huang Y, Liu Z, Cheng Y, Gan Y, Zhou Y, Zhou P, Chen B, Liang C, Liu Z, Li W, Tian J (2018) A new approach to predict progression-free survival in stage IV EGFR-mutant NSCLC patients with EGFR-TKI therapy. Clin Cancer Res 24(15):3583–3592. https://doi.org/10.1158/1078-0432.Ccr-17-2507

CAS  PubMed  Google Scholar 

Song J, Wang L, Ng NN, Zhao M, Shi J, Wu N, Li W, Liu Z, Yeom KW, Tian J (2020) Development and validation of a machine learning model to explore tyrosine kinase inhibitor response in patients with stage IV EGFR variant-positive non-small cell lung cancer. JAMA Netw Open 3(12):e2030442. https://doi.org/10.1001/jamanetworkopen.2020.30442

PubMed  PubMed Central  Google Scholar 

Mu W, Jiang L, Zhang J, Shi Y, Gray JE, Tunali I, Gao C, Sun Y, Tian J, Zhao X, Sun X, Gillies RJ, Schabath MB (2020) Non-invasive decision support for NSCLC treatment using PET/CT radiomics. Nat Commun 11(1):5228. https://doi.org/10.1038/s41467-020-19116-x

CAS  PubMed  PubMed Central  Google Scholar 

Siam L, Bleckmann A, Chaung HN, Mohr A, Klemm F, Barrantes-Freer A, Blazquez R, Wolff HA, Lüke F, Rohde V, Stadelmann C, Pukrop T (2015) The metastatic infiltration at the metastasis/brain parenchyma-interface is very heterogeneous and has a significant impact on survival in a prospective study. Oncotarget 6(30):29254–29267. https://doi.org/10.18632/oncotarget.4201

PubMed  PubMed Central  Google Scholar 

Yoo H, Kim YZ, Nam BH, Shin SH, Yang HS, Lee JS, Zo JI, Lee SH (2009) Reduced local recurrence of a single brain metastasis through microscopic total resection. J Neurosurg 110(4):730–736. https://doi.org/10.3171/2008.8.Jns08448

PubMed  Google Scholar